Compare Cassava Sciences Inc (FLNA) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Norfolk Southern Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Norfolk Southern Corporation trades at $338.26 (market cap $73.79B). The key difference: Norfolk Southern Corporation is far larger — about 1388.6× Cassava Sciences Inc's market cap, and Norfolk Southern Corporation pays a 1.64% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NSC | |
|---|---|---|
Market Cap | $53.14M | $73.79B |
Sector | Health | Technology |
52-Week High | $4.64 | $328.54 |
52-Week Low | $1.09 | $260.32 |
Enterprise Value | -$33.43M | $89.55B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Norfolk Southern (NSC) trades at $335, up 2.5% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI indicates overbought conditions near resistance at $335. Fundamentally, NSC demonstrates robust profitability with 21.9% net margins and consistent earnings beats, though valuation multiples remain elevated. Recent news focuses on the proposed Union Pacific merger, with regulatory scrutiny ongoing.
Outlook remains cautiously optimistic with analyst consensus at $344.40 (2.8% upside). Key opportunities include merger synergies and solid cash flow generation, while risks involve regulatory hurdles for the merger and rich valuations limiting near-term upside. Earnings on July 23 will be critical for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
